Treatments for Open-Angle Glaucoma

Overview of Glaucoma

Glaucoma is a significant cause of irreversible blindness, profoundly impacting individuals’ quality of life. It is estimated that over 70 million people worldwide have suffered vision impairment due to this disease. Furthermore, 10% of individuals who experience blindness in both eyes are affected by glaucoma. Primary open-angle glaucoma is the most common form of this condition, characterized by increased internal eye pressure, which can damage the optic nerve responsible for transmitting visual information to the brain. Elevated pressure may also lead to the death of retinal cells essential for vision. This combination of nerve damage and retinal cell death can result in blind spots, making it increasingly difficult to see.

Risk Factors for Primary Open-Angle Glaucoma

Certain populations are more prone to developing primary open-angle glaucoma. Individuals who are nearsighted, have a family history of glaucoma, belong to African-American descent, or are elderly are at higher risk. Additionally, those receiving steroid injections in their eyes for diabetic complications may face an increased likelihood of developing glaucoma.

Symptoms of Glaucoma

Identifying glaucoma can be challenging, as many individuals do not exhibit symptoms until the disease has progressed significantly. Often, vision defects may occur in one eye, while the other eye compensates for the loss, leading to a lack of awareness about the condition. Consequently, early diagnosis is frequently delayed. If left untreated, glaucoma can lead to severe symptoms, including patchy blind spots in peripheral vision that may escalate to broader vision loss.

Treatment Options for Open-Angle Glaucoma

A recent article in the Cochrane Database of Systematic Reviews noted the absence of standardized guidelines for treating primary open-angle glaucoma. Despite this, various treatment options exist to help manage the condition. Traditionally, the treatment has involved topical and systemic medications aimed at lowering intraocular pressure. Topical drugs are typically administered as eye drops, while systemic medications enter the bloodstream and affect the body more broadly. If patients do not respond adequately to these medications, surgical interventions, such as trabeculectomy, may be necessary to preserve vision.

Available Medications for Glaucoma

With a diverse range of medications available, treatment for glaucoma should be tailored to each patient’s medical history and response to pressure-lowering therapies. Commonly prescribed medications include beta-blockers, brimonidine, epinephrine, and carbonic anhydrase inhibitors, among others.

Future Directions in Open-Angle Glaucoma Treatment

A new multicenter clinical trial in the United States has been exploring the safety and efficacy of a novel treatment called DE-126. Preliminary results indicate that this new drug may effectively reduce intraocular pressure comparable to the widely used beta-blocker timolol. This trial underscores the need for ongoing research to identify less invasive treatment options for patients with open-angle glaucoma.

References

Weinreb, R. N., Aung, T., & Medeiros, F. A. (2014). The pathophysiology and treatment of glaucoma: a review. JAMA, 311(18), 1901–1911. https://doi.org/10.1001/jama.2014.3192

Vass, C., Hirn, C., Sycha, T., Findl, O., Bauer, P., & Schmetterer, L. (2007). Medical interventions for primary open angle glaucoma and ocular hypertension. The Cochrane database of systematic reviews, 2007(4), CD003167. https://doi.org/10.1002/14651858.CD003167.pub3

Patil, N. S., Mihalache, A., Hatamnejad, A., Popovic, M. M., Kertes, P. J., & Muni, R. H. (2022). Intravitreal steroids compared with anti-VEGF treatment for diabetic macular edema: A meta-analysis. Ophthalmology Retina, S2468-6530(22)00494-8. Advance online publication. https://doi.org/10.1016/j.oret.2022.10.008

Schuster, A. K., Erb, C., Hoffmann, E. M., Dietlein, T., & Pfeiffer, N. (2020). The diagnosis and treatment of glaucoma. Deutsches Ärzteblatt international, 117(13), 225–234. https://doi.org/10.3238/arztebl.2020.0225

NCT04742283. (2021). Multicenter study assessing the efficacy and safety of DE-126 ophthalmic solution 0.002% compared with timolol maleate ophthalmic solution 0.5% in subjects with primary open angle glaucoma or ocular hypertension. https://clinicaltrials.gov/show/NCT04742283